Understanding and targeting the underlying mechanisms of resistance and optimizing therapeutic strategies will be crucial for advancing the treatment of colorectal cancer in the field of immunooncology. The PD-1 | colorectal cancer concept pair appears to be on the higher end of the spectrum with average fold increase of >3-fold (Figure ).